ClinicalTrialsFinder
RecruitingNCT06426953

Predictive Effect of TGF-β and INS-PI3K-AKT Related Proteins for POD in Diabetes Patients

Predictive Effect of TGF-β Combined With INS-PI3K-AKT Signaling Pathway Related Proteins (ADNP, MAP6, Pgc-1α) for POD in Diabetes Patients

Sponsor

Xie Kangjie

Enrollment

180 participants

Start Date

May 20, 2024

Study Type

OBSERVATIONAL

Conditions

DiabetesPostoperative Delirium

Summary

To investigate the relationship between POD, TGF-β and INS-PI3K-AKT signaling pathway related proteins (ADNP, MAP6, PGC-1α) in diabetic patients

Eligibility

Min Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying No intervention for people with diabetes and postoperative delirium. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 65 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNo intervention

No intervention

Locations(2)

The People's hospital of Qiannan

Duyun, Guizhou, China

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06426953

Related Trials

Urinary Vitamin C Loss in Diabetic Subjects

NCT000715261 location

Diabetes and Heart Disease Risk in Blacks

NCT000018531 location

A Natural History Study of Metabolic Sizing in Health and Disease

NCT053987831 location

Upstroke Time Measured by Photoplethysmography

NCT057955822 locations

Inflammatory Cytokines and Oxidative Stress Biomarkers in Diabetic Chronic Kidney Disease Patients

NCT076572861 location